Daily Ards Research Analysis
Three ARDS-focused studies stand out today: a randomized ovine experiment shows nebulized epinephrine improves oxygenation and survival during VV-ECMO after smoke inhalation; a multicenter cohort links higher early PEEP to increased AKI risk in COVID-19 ARDS; and a large retrospective cohort identifies admission RDW as an independent predictor of ARDS mortality. Together, they span therapy, ventilator strategy, and prognostication.
Summary
Three ARDS-focused studies stand out today: a randomized ovine experiment shows nebulized epinephrine improves oxygenation and survival during VV-ECMO after smoke inhalation; a multicenter cohort links higher early PEEP to increased AKI risk in COVID-19 ARDS; and a large retrospective cohort identifies admission RDW as an independent predictor of ARDS mortality. Together, they span therapy, ventilator strategy, and prognostication.
Research Themes
- Adjunctive aerosol therapy during ECMO
- Ventilator settings and kidney injury risk in ARDS
- Hematologic biomarkers for ARDS prognosis
Selected Articles
1. Nebulized Epinephrine Improves Oxygenation During Extracorporeal Membrane Oxygenation in Sheep with Smoke Inhalation-Induced Acute Respiratory Distress Syndrome.
In a randomized ovine model of smoke inhalation ARDS supported with VV-ECMO, nebulized epinephrine improved oxygenation at 30–36 hours, reduced airway edema, and increased survival without systemic cardiovascular effects. These data support aerosolized epinephrine as a potential adjunctive therapy during ECMO.
Impact: Demonstrates a feasible, low-cost inhaled intervention that improves survival in a large-animal ECMO ARDS model, a critical translational step. Addresses airway pathology during ECMO, a gap in current practices.
Clinical Implications: Consider pilot clinical trials to test nebulized epinephrine during VV-ECMO for smoke inhalation-associated ARDS, with careful monitoring for cardiovascular effects and dosing optimization to facilitate oxygenation and possibly shorten ECMO duration.
Key Findings
- Randomized comparison (saline vs nebulized epinephrine) in 12 sheep on VV-ECMO after smoke inhalation injury
- Higher survival in the epinephrine group (p = 0.03)
- Significant PaO2/FiO2 improvement at 30 and 36 hours with epinephrine (p < 0.05), with a positive time correlation (r = 0.8, p < 0.01)
- Lower tracheal wet-to-dry weight ratio with epinephrine, indicating reduced airway edema (p < 0.05)
- No significant systemic cardiovascular effects observed
Methodological Strengths
- Randomized controlled design in a conscious large-animal ARDS model on VV-ECMO
- Multimodal outcome assessment (oxygenation, survival, airway edema metrics)
Limitations
- Small sample size (n=12) limits precision
- Preclinical smoke inhalation model may not generalize to all ARDS etiologies and human ECMO settings
Future Directions: Conduct dose-finding and safety studies, followed by pilot RCTs in ECMO-supported ARDS populations (especially smoke inhalation) to evaluate effects on oxygenation, ventilator settings, and ECMO duration.
INTRODUCTION: Smoke inhalation injury induces airway edema, obstruction, and bronchospasm leading to hypoxia and acute respiratory distress syndrome (ARDS). When ARDS is refractory to conventional therapy, veno-venous extracorporeal membrane oxygenation (VV ECMO) is used as a rescue strategy. We hypothesized that nebulized epinephrine improves oxygenation by alleviating airway dysfunction during VV ECMO support. METHODS: Twelve female Merino sheep were surgically instrumented and subjected to smoke inhalation injury. VV ECMO was initiated when the PaO₂/FiO₂ ratio dropped below 150 mmHg. Sheep were randomized to receive either saline nebulization (control group, n = 7) or epinephrine nebulization (treatment group, n = 5) every 4 h. Extracorporeal membrane oxygenation (ECMO) blood flow was maintained at 60-80 mL/kg/min; the sheep remained conscious in cages after ECMO initiation. Cardiopulmonary variables, blood gases, and respiratory mechanics were monitored for 72 h. RESULTS: Survival was significantly higher in the treatment group (p = 0.03). The PaO₂/FiO₂ ratio improved significantly in the treatment group at 30 and 36 h compared to the control group (p < 0.05) with a positive correlation between oxygenation and time (correlation coefficient = 0.8, p < 0.01). The tracheal wet-to-dry weight ratio was lower in the treatment group (p < 0.05) indicating reduced airway edema. No significant systemic cardiovascular effects were observed. CONCLUSION: This study demonstrates, nebulized epinephrine improved oxygenation, reduced airway edema, and enhanced survival in an ovine model of smoke inhalation-induced ARDS supported with VV ECMO. These findings suggest that epinephrine nebulization may provide a promising adjunctive therapy to improve outcomes and facilitate shorter ECMO duration in smoke inhalation-associated ARDS.
2. PEEP-AKI-COVID ICU: Effect of positive end-expiratory pressure on acute kidney injury development in patients with COVID-19-associated acute respiratory distress syndrome: an ancillary analysis of the COVID-ICU study.
This multicenter ancillary analysis found that in 1,066 mechanically ventilated COVID-19 ARDS patients with normal pre-intubation renal function, 48% developed AKI within 5 days, and higher early mean PEEP independently increased AKI risk. It highlights the need to balance oxygenation targets with renal protection when titrating PEEP.
Impact: Quantifies a clinically meaningful association between early PEEP and AKI in a large, prospective, multicenter cohort, informing ventilatory strategies beyond oxygenation alone.
Clinical Implications: When titrating PEEP in COVID-19 ARDS, consider individualized, hemodynamically informed strategies (e.g., assessing driving pressure, venous congestion) to mitigate renal risk, especially during the first 3–5 days after intubation.
Key Findings
- Analyzed 1,066 ventilated COVID-19 ARDS patients with normal pre-intubation renal function
- 48% developed AKI within 5 days after intubation (KDIGO criteria)
- Higher early mean PEEP (first 3 days) independently associated with AKI (OR 1.10; 95% CI 1.05–1.16)
- Association evaluated using multivariable logistic regression
Methodological Strengths
- Prospective, international, multicenter cohort with large sample size
- Adjusted analyses with predefined KDIGO outcome criteria
Limitations
- Observational design cannot establish causality; residual confounding possible
- Findings primarily reflect COVID-19 ARDS and early ventilation period; generalizability to non-COVID ARDS uncertain
Future Directions: Test PEEP titration strategies that integrate kidney-protective targets (e.g., venous congestion reduction) in pragmatic trials, and validate thresholds for AKI risk across ARDS phenotypes.
BACKGROUND: Acute Kidney Injury (AKI) is common in patients admitted to the intensive care unit (ICU) for severe SARS-CoV-2 pneumonia and is associated with a worse prognosis. Mechanical ventilation has been identified as a risk factor for renal damage in COVID-19. However, few studies have examined the specific ventilatory settings involved. We hypothesized that positive end-expiratory pressure (PEEP) may contribute to the onset of AKI. Our primary objective was to assess the relationship between PEEP levels and the development of AKI in critically ill patients with COVID-19-related ARDS. METHODS: We conducted an ancillary analysis of the international, prospective, multicenter COVID-ICU study, which included 4244 COVID-19 ICU patients across 149 intensive care units. For our study, only patients who underwent mechanical ventilation for at least 48 h and had normal renal function before intubation were included. The primary outcome was AKI, defined according to Kidney Disease Improving Global Outcomes (KDIGO) criteria. A multivariable logistic regression model was used to evaluate the association between PEEP levels and the development of AKI (KDIGO score > 1). RESULTS: A total of 1,066 patients were included in the analysis. Among them, 510 (48%) developed AKI within the first 5 days after intubation. After multivariable adjustment, higher daily mean PEEP levels, averaged over the first 3 days of mechanical ventilation and treated as a continuous variable, were independently associated with the development of AKI (odds ratio [OR] 1.10; 95% confidence interval [CI] 1.05-1.16). A PEEP level exceeding 15.2 cmH CONCLUSION: In patients with COVID-19-related ARDS patients, higher PEEP levels within the first 5 days after intubation were independently associated with AKI. These findings underscore the importance of ventilatory strategies to balance oxygenation and kidney protection.
3. Red Blood Cell Distribution Width (RDW) as Predictor of the Clinical Course and Mortality in Patients With Acute Respiratory Distress Syndrome (ARDS): A Retrospective Study.
In a 1,037-patient retrospective ARDS cohort, higher admission RDW was associated with mortality and adverse clinical course, with predictive performance supported by logistic/Cox models and ROC analyses. RDW may be a simple, readily available biomarker for ARDS risk stratification.
Impact: Leverages a large ARDS cohort to propose a low-cost, routinely available hematologic measure as a mortality predictor, facilitating bedside risk stratification.
Clinical Implications: Incorporate RDW into ARDS prognostic assessments alongside severity scores, with attention to potential confounders (e.g., anemia, iron status), and evaluate dynamic RDW changes during ICU stay.
Key Findings
- Retrospective analysis of 1,037 adult ARDS ICU patients (2007–2019) at a referral center
- Non-survivors had higher admission RDW than survivors (median 16.55% vs 15.4%)
- Mortality prediction supported by logistic regression, Cox regression, and ROC analyses with thresholds identified via Youden’s method
Methodological Strengths
- Large sample size from a specialized ARDS center
- Multiple statistical approaches (logistic, Cox, ROC) to validate predictive value
Limitations
- Retrospective single-center design limits generalizability and may harbor unmeasured confounding
- RDW influenced by comorbidities (e.g., anemia, iron deficiency) not fully captured
Future Directions: Prospectively validate RDW-based thresholds across diverse ARDS populations and integrate RDW into multivariable risk models with dynamic updates.
BACKGROUND AND AIMS: Evidence on the prognostic value of red blood cell distribution width (RDW) in critically ill patients with acute respiratory distress syndrome (ARDS) is limited. This study evaluated RDW as a predictor of mortality in patients with ARDS. METHODS: A retrospective study conducted at an ARDS referral center included 1037 adult ICU patients (2007-2019). RDW values at ICU admission and during ICU stay were evaluated for their ability to predict mortality using statistical analyses, including logistic regression, Cox regression, and receiver operating curve analysis, and further specified according to Youden's method. RESULTS: In total, 1037 ICU patients with ARDS were included in the analysis. Non-survivors had significantly higher RDW on ICU admission than survivors (survivors' median RDW 15.4% [14.2; 17.0%] vs. non-survivors' median RDW 16.55% [15.2; 18.0%]; CONCLUSION: RDW at ICU admission predicts mortality and clinical course in ARDS patients. RDW may serve as a reliable marker of ARDS severity and mortality risk in the ICU.